JP2016513723A5 - - Google Patents

Download PDF

Info

Publication number
JP2016513723A5
JP2016513723A5 JP2016502690A JP2016502690A JP2016513723A5 JP 2016513723 A5 JP2016513723 A5 JP 2016513723A5 JP 2016502690 A JP2016502690 A JP 2016502690A JP 2016502690 A JP2016502690 A JP 2016502690A JP 2016513723 A5 JP2016513723 A5 JP 2016513723A5
Authority
JP
Japan
Prior art keywords
composition
item
formulated
thiosemicarbazone
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2016502690A
Other languages
English (en)
Japanese (ja)
Other versions
JP6293258B2 (ja
JP2016513723A (ja
Filing date
Publication date
Priority claimed from US13/803,482 external-priority patent/US20140271812A1/en
Application filed filed Critical
Publication of JP2016513723A publication Critical patent/JP2016513723A/ja
Publication of JP2016513723A5 publication Critical patent/JP2016513723A5/ja
Application granted granted Critical
Publication of JP6293258B2 publication Critical patent/JP6293258B2/ja
Expired - Fee Related legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2016502690A 2013-03-14 2014-03-14 化学療法誘発認知障害の処置 Expired - Fee Related JP6293258B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US13/803,482 2013-03-14
US13/803,482 US20140271812A1 (en) 2013-03-14 2013-03-14 Treatment for chemotherapy-induced cognitive impairment
PCT/US2014/028039 WO2014152864A1 (en) 2013-03-14 2014-03-14 Treatment for chemotherapy-induced cognitive impairment

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2018013721A Division JP2018062537A (ja) 2013-03-14 2018-01-30 化学療法誘発認知障害の処置

Publications (3)

Publication Number Publication Date
JP2016513723A JP2016513723A (ja) 2016-05-16
JP2016513723A5 true JP2016513723A5 (https=) 2017-04-13
JP6293258B2 JP6293258B2 (ja) 2018-03-14

Family

ID=51528048

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2016502690A Expired - Fee Related JP6293258B2 (ja) 2013-03-14 2014-03-14 化学療法誘発認知障害の処置
JP2018013721A Withdrawn JP2018062537A (ja) 2013-03-14 2018-01-30 化学療法誘発認知障害の処置

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2018013721A Withdrawn JP2018062537A (ja) 2013-03-14 2018-01-30 化学療法誘発認知障害の処置

Country Status (5)

Country Link
US (1) US20140271812A1 (https=)
EP (1) EP2968319B1 (https=)
JP (2) JP6293258B2 (https=)
CA (1) CA2905403A1 (https=)
WO (1) WO2014152864A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2984379C (en) * 2015-04-28 2024-06-11 Newsouth Innovations Pty Limited Targeting nad+ to treat chemotherapy and radiotherapy induced cognitive impairment, neuropathies, and inactivity
WO2019147839A1 (en) * 2018-01-24 2019-08-01 Sensei Biotherapeutics, Inc. Methods and compositions for preserving neurogenesis
WO2022138842A1 (ja) * 2020-12-24 2022-06-30 参天製薬株式会社 エピナスチン又はその塩と硫黄系抗酸化剤を含有する経皮投与用医薬組成物

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4447427A (en) 1979-01-04 1984-05-08 The United States Of America As Represented By The Secretary Of The Army Method for treating bacterial infections with 2-acetyl- and 2-propionylpyridine thiosemicarbazones
US5180831A (en) * 1990-08-10 1993-01-19 Georgia Tech Research Corporation Quaternary pyridinium compounds
US5281715A (en) 1992-05-13 1994-01-25 Yale University 2-formylpyridine thiosemicarbazone compounds
US6114376A (en) * 1997-04-30 2000-09-05 Mcgill University Methods for using macrocyclic lactone compounds as multidrug resistance reversing agents in tumor and other cells
US5869676A (en) 1997-05-15 1999-02-09 Vion Pharmaceuticals, Inc. Process for the synthesis of ribonucleotide reductase inhibitors 3-AP and 3-AMP
US5767134A (en) 1997-05-15 1998-06-16 Vion Pharmaceuticals, Inc. Prodrug forms of ribonucleotide reductase inhibitors 3-AP and 3-AMP
EP1626718A4 (en) 2003-05-01 2010-05-05 Panacea Pharmaceuticals Inc METHOD FOR THE TREATMENT OF ISCHEMIC ILLNESSES
US20060194810A1 (en) 2004-04-30 2006-08-31 Bijan Almassian Methods of treating ischemic related conditions
US20070243132A1 (en) * 2005-12-22 2007-10-18 Apollo Life Sciences Limited Transdermal delivery of pharmaceutical agents
US20080039471A1 (en) * 2006-08-14 2008-02-14 Ghanbari Hossein A Composition and method to inhibit tissue plasminogen activator (tPA) - potentiated neurotoxicity
EP2121681B1 (en) * 2007-01-11 2015-04-15 Critical Outcome Technologies, Inc. Compounds and method for treatment of cancer
US20090286799A1 (en) * 2008-05-16 2009-11-19 Zhi-Gang Jiang Methods for the treatment of brain edema
WO2010054260A1 (en) * 2008-11-07 2010-05-14 Biotie Therapies Gmbh Imidazo[5,1-c][1,2,4]benzotriazine derivatives as inhibitors of phosphodiesterases
EP2379493B1 (en) * 2008-12-12 2015-10-14 The University of Melbourne Process for the preparation of asymmetrical bis(thiosemicarbazones)
CN111789956B (zh) * 2011-04-27 2023-02-17 耶鲁大学 用于抑制化疗引起副作用的药物治疗、筛选技术和试剂盒

Similar Documents

Publication Publication Date Title
UA124347C2 (uk) Циклічна динуклеотидна сполука
MX384836B (es) Agentes antivirales contra la hepatitis b
JP2016503793A5 (https=)
CL2021002747A1 (es) Agentes antivirales para la hepatitis b (solicitud divisional no. 487-2020)
UY37998A (es) Agentes antivirales contra la hepatitis b
NZ734019A (en) Novel micro-dystrophins and related methods of use
BR112015022197A8 (pt) uso de um composto para fabricação de um medicamento ou composição farmacêutica para o tratamento de cataplexia
JP2016510326A5 (https=)
EP3954679A3 (en) Amide compounds for the treatment of hiv infections
JP2016517851A5 (https=)
PE20161218A1 (es) (2s)-n-[(1s)-1-ciano-2-feniletil]-1,4-oxazepan-2-carboxamidas como inhibidores de dipeptidil peptidasa 1
JP2018515557A5 (https=)
JP2015110588A5 (https=)
JP2015051983A5 (https=)
NI201800014A (es) Inhibidor de la isocitrato deshidrogenasa mutada idh1 r132h
JP2016503797A5 (https=)
JP2018501215A5 (https=)
EA201791993A1 (ru) Способы лечения протеинопатий
AR092993A1 (es) Laquinimod para reducir el daño talamico en la esclerosis multiple
JP2015521156A5 (https=)
MD4760B1 (ro) Compoziţii şi metode de tratament al infecţiilor provocate de viruşii hepatitei B şi hepatitei D
RU2014117707A (ru) Способ лечения пролиферативного заболевания
RU2016111704A (ru) Производные дезоксинойиримицина и способы их применения
RU2018101431A (ru) Ингибиторы индоламин-2,3-диоксигеназы
JP2018521056A5 (https=)